Stryker’s Trevo® Retriever is the first therapy in 20 years to be declared a front-line treatment to reduce disability in ischemic stroke

KALAMAZOO, MICHIGAN (PRWEB)

The Food and Drug Administration (FDA) expanded on Sept. 2 the indication for Stryker’s Trevo Retriever as front-line treatment to reduce disability in patients experiencing acute ischemic stroke. Trevo is the first and only thrombectomy device to receive this expanded indication, which has the potential to help the hundreds of thousands of Americans who experience ischemic strokes—or brain attacks—each year.

People suffering from stroke commonly experience devastating disabilities and loss of independence due to impaired movement, paralysis, loss of speech and memory. Randomized clinical data using the Trevo retriever alongside IV t-PA shows that patients are almost twice as likely to be functionally independent at 90 days after a stroke compared to medical management alone.1 The strength of this data resulted in Trevo receiving the first and only FDA clearance for a thrombectomy device to significantly reduce disability in patients with ischemic stroke. This clearance for front-line use expands the treatment with Trevo to a broader group of patients.

Read the full article:

PRWeb